Scholarlink

<p>This study aimed to evaluate the anti-obesity effect of <i>Bifidobacterium adolescentis</i> SPM2022 (SPM2022). Culture supernatant of SPM2022 reduced lipid accumulation (<i>p</i> &lt; 0.01) and expression of adipogenic genes (<i>p</i> &lt; 0.001) during 3T3‐L1 differentiation. The effects on anti-obesity and lipid metabolism were assessed in the high fat diet (HFD)-induced obese C57BL6 mouse after 4&#xa0;weeks of obese induction. Experimental groups (<i>n</i> = 6/group): normal diet, HFD, and HFD fed with 10<sup>9</sup>&#xa0;CFU/day of SPM2022. After 5&#xa0;weeks, the weight gain of SPM2022 group was reduced by 72% and the weight of mesenteric fat was reduced by 60% in the SPM2022 compared to the HFD group. The expression of FABP4, CD36 and leptin in epididymis were decreased to 4.5, 2 and twofold respectively in the SPM2022 compared to HFD group. Based on these results, SPM2022 has the potential to be used as a therapeutic agent for addressing obesity and lipid metabolism.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Anti-obesity effect of Bifidobacterium adolescentis SPM2022, isolated from Korean adult

  • 期刊论文

  • 发表日期：

    2025年10月10日

查看全文
  • So Won Kang,
  • Sungsook Choi

摘要

This study aimed to evaluate the anti-obesity effect of Bifidobacterium adolescentis SPM2022 (SPM2022). Culture supernatant of SPM2022 reduced lipid accumulation (p < 0.01) and expression of adipogenic genes (p < 0.001) during 3T3‐L1 differentiation. The effects on anti-obesity and lipid metabolism were assessed in the high fat diet (HFD)-induced obese C57BL6 mouse after 4 weeks of obese induction. Experimental groups (n = 6/group): normal diet, HFD, and HFD fed with 109 CFU/day of SPM2022. After 5 weeks, the weight gain of SPM2022 group was reduced by 72% and the weight of mesenteric fat was reduced by 60% in the SPM2022 compared to the HFD group. The expression of FABP4, CD36 and leptin in epididymis were decreased to 4.5, 2 and twofold respectively in the SPM2022 compared to HFD group. Based on these results, SPM2022 has the potential to be used as a therapeutic agent for addressing obesity and lipid metabolism.